Head and neck.

2 Phase 1 studies recruiting right now, most recently updated first.

Head and neck2 studies

Resectable Locally Advanced Head and Neck Squamous Cell CarcinomaNCT07455032

Neoadjuvant CADI-05 + Pembrolizumab

Neoadjuvant CADI-05 in Combination With Pembrolizumab for Surgically Resectable Locally Advanced Head and Neck Squamous Cell Carcinomas

Fox Chase Cancer CenterOpen the brief

Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaNCT06868433

TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer

Emory UniversityOpen the brief